BeyondSpring的Plinabulin在预防化学性中性粒细胞减少症方面显示积极作用

一项评估BeyondSpring（BYSI -4％）的普那布林与Amgen（AMGN -1.9％）的Neulasta（pegfilgrastim）联合用于预防化学性中性白细胞减少症（CIN）低和骨痛的2期临床试验表明，治疗效果：50％接受高危TAC（多西他赛，阿霉素和环磷酰胺）化疗的患者同时接受Plinabulin + Neulasta的3级（严重）或4级（危及生命的）中性粒细胞减少症，而仅接受Neulasta的81％（ p = 0.0456）。在Plinabulin组中，3/4级中性粒细胞减少症的持续时间为0.94天，而仅Neulasta组为1.38天。接受Plinabulin + Neulasta治疗的患者中至少有1天出现骨痛，而仅接受Neulasta的患者为95％（ p<0.0001).Plinabulin is a marine-derived small molecule that contributes to the prevention of neutropenia by activating a protein called GEF-H1 that plays a key role in signaling pathways affecting the levels of neutrophils.Neutropenia is an abnormally low level of neutrophils (a type of white blood cell that plays a key role in fighting infections) in the blood.The current standard of care for treating CIN is G-CSF agents like Neulasta or Neupogen (filgrastim), but they are associated with bone pain and do not eliminate the risk of grade 3/>中性粒细胞减少症。股价下跌4％，但仅跌至约7,300股。量化价值股票筛选器的性能-2018年第一季度至第三季度